Liver Cancer
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved Opdivo with Yervoy for the first-line treatment of adult patients with unresectable or ...
APRIL 14, 2025
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
MARCH 16, 2022
Survey Documents Pandemic’s Toll On Liver Cancer Screening
Clinicians and patients faced significant disruption in liver cancer screening during the early COVID-19 pandemic, ...
NOVEMBER 10, 2021
For Cirrhotics With HCV, Monitoring for Liver Cancer Warranted Even After Viral Eradication
Although recent advances in direct-acting antiviral therapy have made sustained virologic response (SVR) a reality ...
MARCH 5, 2021
Hep C Cure Linked to Lower Mortality From Liver Cancer
Curing he hepatitis C infection appears to dramatically improve five-year survival rates in people with liver ...
MARCH 17, 2020
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Aspirin Lowers HCC Risk in Hep B Patients
Daily aspirin is significantly associated with a reduced risk for liver cancer in patients with hepatitis B virus, ...
APRIL 4, 2018
